Literature DB >> 1931885

Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation.

T M Bocan1, S B Mueller, P D Uhlendorf, R S Newton, B R Krause.   

Abstract

Due to the potential importance of acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) in the generation of lipid-filled monocytes-macrophages, the ACAT inhibitor CI-976 (2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide) was evaluated relative to selected lipid-lowering agents for their effect on atherosclerotic lesion regression and progression. Atherosclerotic lesions comparable in composition to human fatty streaks were induced by chronic endothelial denudation in the iliac-femoral artery of hypercholesterolemic New Zealand White rabbits before intervention, while naturally occurring fatty streaks developed in the thoracic aorta. CI-976 administered in a hypercholesterolemic diet at a dose that did not lower plasma cholesterol prevented the accumulation of monocytes-macrophages within the preestablished iliac-femoral lesion and reduced the foam cell area by 27-29% relative to the initiation of intervention. CI-976 also blunted the development of thoracic aortic fatty streak-like lesions and decreased the cholesteryl ester enrichment by 46%. CI-976 had no effect on plasma triglycerides and, more importantly, had no effect or decreased liver, iliac-femoral, and thoracic aortic free cholesterol content. Dietary intervention alone increased monocyte-macrophage involvement in the iliac-femoral lesion despite reductions in plasma, liver, and thoracic aortic cholesterol content. Conventional lipid-lowering therapy such as cholestyramine or cholestyramine/niacin required substantial decreases in plasma cholesterol levels to achieve comparable vascular changes. We conclude that inhibition of ACAT within the arterial wall by the potent and specific ACAT inhibitor CI-976, even in the absence of plasma cholesterol lowering, can result in the inhibition of atherosclerotic lesion progression and can enhance regression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1931885     DOI: 10.1161/01.atv.11.6.1830

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  17 in total

1.  Effect of trifluoperazine on certain arterial wall lipid-metabolizing enzymes inducing atherosclerosis in rhesus monkeys.

Authors:  A Mohindroo; P Ahluwalia
Journal:  Lipids       Date:  1997-08       Impact factor: 1.880

Review 2.  Bioactive peptides and proteins from foods: indication for health effects.

Authors:  Niels Peter Möller; Katharina Elisabeth Scholz-Ahrens; Nils Roos; Jürgen Schrezenmeir
Journal:  Eur J Nutr       Date:  2008-05-27       Impact factor: 5.614

3.  Inhibition of Acyl-CoA: cholesterol acyltransferase (ACAT), overexpression of cholesterol transporter gene, and protection of amyloid β (Aβ) oligomers-induced neuronal cell death by tricyclic pyrone molecules.

Authors:  Laxman Pokhrel; Izumi Maezawa; Thi D T Nguyen; Kyeong-Ok Chang; Lee-Way Jin; Duy H Hua
Journal:  J Med Chem       Date:  2012-10-05       Impact factor: 7.446

4.  Modulation of endosomal cholesteryl ester metabolism by membrane cholesterol.

Authors:  Yan Wang; Adam B Castoreno; Walter Stockinger; Axel Nohturfft
Journal:  J Biol Chem       Date:  2005-01-18       Impact factor: 5.157

5.  Human acyl-CoA:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma.

Authors:  Bao-Liang Song; Can-Hua Wang; Xiao-Min Yao; Li Yang; Wen-Jing Zhang; Zhen-Zhen Wang; Xiao-Nan Zhao; Jin-Bo Yang; Wei Qi; Xin-Ying Yang; Kenji Inoue; Zhi-Xin Lin; Hui-Zhan Zhang; Tatsuhiko Kodama; Catherine C Y Chang; Yin-Kun Liu; Ta-Yuan Chang; Bo-Liang Li
Journal:  Biochem J       Date:  2006-03-15       Impact factor: 3.857

6.  Down-regulation of hormone-sensitive lipase in sterol ester-laden J774.2 macrophages.

Authors:  C A Jepson; J A Harrison; F B Kraemer; S J Yeaman
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

7.  Inhibition of cholesterol esterification in macrophages and vascular smooth muscle foam cells: evaluation of E5324, an acyl-CoA cholesterol acyltransferase inhibitor.

Authors:  A C Nicholson; K B Pomerantz; T Fujimori; D P Hajjar
Journal:  Lipids       Date:  1995-08       Impact factor: 1.880

8.  In vitro exploration of ACAT contributions to lipid droplet formation during adipogenesis.

Authors:  Yuyan Zhu; Chih-Yu Chen; Junjie Li; Ji-Xin Cheng; Miran Jang; Kee-Hong Kim
Journal:  J Lipid Res       Date:  2018-03-16       Impact factor: 5.922

9.  Lipid-lowering effects of WAY-121,898, an inhibitor of pancreatic cholesteryl ester hydrolase.

Authors:  B R Krause; D R Sliskovic; M Anderson; R Homan
Journal:  Lipids       Date:  1998-05       Impact factor: 1.880

10.  Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages.

Authors:  S Fazio; A S Major; L L Swift; L A Gleaves; M Accad; M F Linton; R V Farese
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.